SANDRA OLSON: Open Payments
NPI 1861890683 · GRAND RAPIDS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$594 in 12 payments from 10 companies in 2025. Trend: 2023 $282 · 2024 $133 · 2025 $594
Food & beverage: $594
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 3 | $205 |
| Novo Nordisk Inc | 1 | $121 |
| Boston Scientific Corporation | 1 | $113 |
| Janssen Biotech, Inc. | 1 | $30 |
| Ipsen Biopharmaceuticals, Inc | 1 | $28 |
| Gilead Sciences, Inc. | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Ardelyx, Inc. | 1 | $19 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
Products named: REZDIFFRA, Wegovy, EXALT Model D, TREMFYA, IQIRVO, INJECTAFER, IBSRELA, XIFAXAN.
Industry payments across MI — which companies pay providers there.
